AIMZ Investment Advisors LLC trimmed its position in Teva Pharmaceutical Industries Ltd (NYSE:TEVA) by 11.6% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 132,020 shares of the company’s stock after selling 17,272 shares during the quarter. Teva Pharmaceutical Industries makes up 1.9% of AIMZ Investment Advisors LLC’s holdings, making the stock its 16th largest position. AIMZ Investment Advisors LLC’s holdings in Teva Pharmaceutical Industries were worth $2,502,000 at the end of the most recent reporting period.
Several other hedge funds have also recently modified their holdings of TEVA. Zurcher Kantonalbank Zurich Cantonalbank grew its stake in Teva Pharmaceutical Industries by 1.6% in the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 198,178 shares of the company’s stock valued at $3,755,000 after buying an additional 3,100 shares during the last quarter. WealthTrust Axiom LLC grew its stake in Teva Pharmaceutical Industries by 29.9% in the 4th quarter. WealthTrust Axiom LLC now owns 14,948 shares of the company’s stock valued at $283,000 after buying an additional 3,440 shares during the last quarter. Argyle Capital Management Inc. grew its stake in Teva Pharmaceutical Industries by 6.3% in the 4th quarter. Argyle Capital Management Inc. now owns 60,750 shares of the company’s stock valued at $1,151,000 after buying an additional 3,598 shares during the last quarter. Oak Associates Ltd. OH grew its stake in Teva Pharmaceutical Industries by 1.1% in the 3rd quarter. Oak Associates Ltd. OH now owns 384,224 shares of the company’s stock valued at $6,762,000 after buying an additional 4,300 shares during the last quarter. Finally, Stephens Inc. AR grew its stake in Teva Pharmaceutical Industries by 13.5% in the 4th quarter. Stephens Inc. AR now owns 36,813 shares of the company’s stock valued at $698,000 after buying an additional 4,381 shares during the last quarter. 58.22% of the stock is currently owned by institutional investors.
A number of research analysts recently commented on the stock. Vetr lowered shares of Teva Pharmaceutical Industries from a “strong-buy” rating to a “buy” rating and set a $22.63 price target on the stock. in a research note on Thursday, January 11th. ValuEngine upgraded shares of Teva Pharmaceutical Industries from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 11th. Zacks Investment Research lowered shares of Teva Pharmaceutical Industries from a “hold” rating to a “sell” rating in a research note on Friday, January 12th. BTIG Research lowered shares of Teva Pharmaceutical Industries from a “buy” rating to a “neutral” rating and set a $24.00 price target on the stock. in a research note on Thursday, January 18th. They noted that the move was a valuation call. Finally, Leerink Swann increased their target price on shares of Teva Pharmaceutical Industries from $15.00 to $17.00 and gave the stock an “underperform” rating in a research report on Friday, January 26th. Ten analysts have rated the stock with a sell rating, fourteen have assigned a hold rating and eight have given a buy rating to the company. Teva Pharmaceutical Industries presently has a consensus rating of “Hold” and an average price target of $20.81.
Teva Pharmaceutical Industries (NYSE:TEVA) last issued its quarterly earnings data on Thursday, February 8th. The company reported $0.91 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $0.77 by $0.14. The business had revenue of $5.46 billion during the quarter, compared to the consensus estimate of $5.29 billion. Teva Pharmaceutical Industries had a negative net margin of 72.66% and a positive return on equity of 16.43%. The firm’s revenue was down 15.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.38 EPS. equities analysts expect that Teva Pharmaceutical Industries Ltd will post 2.31 earnings per share for the current year.
In related news, EVP Mark Sabag sold 5,050 shares of the stock in a transaction that occurred on Thursday, February 15th. The shares were sold at an average price of $19.68, for a total value of $99,384.00. Following the completion of the transaction, the executive vice president now owns 44,517 shares of the company’s stock, valued at approximately $876,094.56. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. In the last three months, insiders sold 7,636 shares of company stock valued at $149,390. 7.10% of the stock is owned by insiders.
COPYRIGHT VIOLATION WARNING: This article was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.americanbankingnews.com/2018/03/13/teva-pharmaceutical-industries-ltd-teva-shares-sold-by-aimz-investment-advisors-llc.html.
About Teva Pharmaceutical Industries
Teva Pharmaceutical Industries Limited is a pharmaceutical company. The Company is engaged in developing, producing and marketing generic medicines and a portfolio of specialty medicines. The Company operates through two segments: Generic medicines and Specialty medicines. The Company develops, manufactures and sells generic medicines in a range of dosage forms, including tablets, capsules, injectables, inhalants, liquids, ointments and creams.
Want to see what other hedge funds are holding TEVA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Teva Pharmaceutical Industries Ltd (NYSE:TEVA).
Receive News & Ratings for Teva Pharmaceutical Industries Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teva Pharmaceutical Industries and related companies with MarketBeat.com's FREE daily email newsletter.